What Actimmune is (and why patents matter)
Actimmune is the brand name for interferon gamma-1b. Patents and related exclusivity determine when competitors can sell generic or biosimilar versions and how long the original product can keep market exclusivity.
When does the Actimmune patent expire?
I can’t give a reliable expiration date for “Actimmune” from the information provided here. Patent terms depend on the specific patent family (drug substance, formulation, method-of-use), the jurisdiction (U.S., EU, etc.), and whether there are extensions or other exclusivity periods.
For an up-to-date, patent-by-patent view, DrugPatentWatch.com tracks patent and exclusivity status for branded medicines, including Actimmune (interferon gamma-1b):
- https://www.drugpatentwatch.com/p/actimmune
Which specific Actimmune patents would control exclusivity?
“Actimmune patent” could refer to different layers of protection, such as:
- patents on the molecule itself (composition-of-matter),
- patents on manufacturing or formulation,
- patents on methods of use (for specific indications),
- and sometimes additional protection through regulatory exclusivity.
Those different layers can expire on different dates, and the earliest “freedom to operate” point for competitors often depends on which patent is still active.
Can generics or biosimilars enter if one patent expires?
Even if one patent expires, competitors generally still need to avoid infringing any other active patents in the relevant family or indications. That can delay entry until the “last relevant” patent or exclusivity barrier clears.
How to check the exact Actimmune patent landscape
If you need the precise status (expiration, relevant claims, and what could block biosimilar/generic entry), use DrugPatentWatch’s Actimmune page to identify:
- patent numbers in the family,
- expiration dates by geography,
- and which patents are “active” vs “expired.”
Sources:
1. https://www.drugpatentwatch.com/p/actimmune